Skip to main content

Pressure BioSciences Completes Second Tranche of Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences said after the close of the market Tuesday that it has completed the second tranche of its private placement raising gross proceeds of $275,475.

In the second tranche of the offering, the firm sold 22,038 units to two accredited investors for $12.50 per unit. Each unit consists of one share of Series C convertible preferred stock, which is convertible into 10 shares of common stock, and a warrant to purchase 10 shares of common stock at an exercise price equal to $2.13 per share, which is exercisable until the third anniversary of the date of issuance.

Pressure Bio disclosed in the filing with the US Securities and Exchange Commission that it had entered into an agreement with the investors to lower the price of the units from $15 each to $12.50 each. As a result, the firm issued an additional 11,011 units to investors who participated in the earlier closings on April 8 and April 11.

Pressure Bio has raised total gross proceeds of $1.1 million thus far from the private placement.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.